# Ciliatech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ciliatech

- Industry: Healthcare Specialists
- Headquarters: France
- Website: www.cilia.tech
- Total disclosed funding: $3.1M
- Latest round: Series A (Apr 25, 2023)
- Investors on record: 3

## About

Based in France, and founded in 2017 by co-founders Philippe Sourdille and Olivier Benoit, Ciliatech offers cilia-scleral inter-positioning device technology that treats open-angle glaucoma. The accumulation of aqueous humor, fluid in the eye, leads to glaucoma. This causes the intraocular pressure (IOP) to increase, which damages the optic nerve and leads to vision loss. In April 2023, Ciliatech raised EUR 1.75 million in venture funding.

The company developed the CID (Cilio-Scleral Inter-positioning Device) to effectively reduce intraocular pressure (IOP) without penetrating the anterior chamber or creating subconjunctival filtration critical measures, enabling eye surgeons to overcome the complications and shortcomings of other glaucoma surgical techniques. This offers the unparalleled advantage of unlocking the natural uveoscleral pathway while leaving the anterior chamber fully intact, along with the wall that separates it from the supraciliary space.

## Funding rounds

- Series A, Apr 25, 2023, $1.9M — Kreaxi, BNP Paribas Developpement
- Series B, Sep 27, 2021, $0.6M — Kreaxi, BNP Developpement
- Series B, May 2, 2018, $0.6M — Kreaxi, BNP Paribas Developpement

## Investors

- Kreaxi (https://capitalatlas.ai/funds/kreaxi) — Series B, Series A
- BNP Paribas Developpement (https://capitalatlas.ai/funds/bnp-paribas-developpement) — Series B, Series A
- BNP Developpement — Series B